Significant improvement in overall survival seen in the all-comer population of 2L ESCC1
8.6 months of median overall survival with TEVIMBRA vs 6.3 months with chemotherapy alone in the all-comer population
Clinically meaningful response rates in the all-comer population
- 15.2% ORR with TEVIMBRA (95% CI: 11.1-20.2) vs 6.6% ORR with chemotherapy (95% CI: 3.9-10.4)
TEVIMBRA demonstrated extended overall survival and clinically meaningful responses in the all-comer population
1L, first line; 2L, second line; ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; mOS, median overall survival; ORR, overall response rate; OS, overall survival; PD-L1, programmed death ligand 1.
References: 1. TEVIMBRA. Prescribing Information. San Mateo, CA: Beigene, Ltd.; 2025. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed April 22, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.